Alaunos Therapeutics Announces Third Quarter 2023 Financial Results, Phase 1 Clinical Data and Continued Exploration of Strategic Alternatives
14 nov. 2023 07h30 HE
|
Alaunos Therapeutics, Inc.
TCR-T Library Phase 1/2 trial achieved an 87% disease control rate of eight evaluable patients with metastatic, refractory solid tumors; TCR-T cell therapy was well tolerated in all treated...
Alaunos Therapeutics Announces Second Quarter 2023 Financial Results, Interim Clinical Data and Exploration of Strategic Alternatives
14 août 2023 16h05 HE
|
Alaunos Therapeutics, Inc.
TCR-T Library Phase 1/2 trial achieved an 83% disease control rate of six evaluable patients with metastatic, refractory solid tumors; TCR-T cell therapy was well tolerated in all evaluable...
Alaunos Therapeutics Announces Presentation at the 2nd Hawaii Global Summit on Thoracic Malignancies
29 juin 2023 07h00 HE
|
Alaunos Therapeutics, Inc.
HOUSTON, June 29, 2023 (GLOBE NEWSWIRE) -- Alaunos Therapeutics, Inc. (“Alaunos” or the “Company”) (Nasdaq: TCRT), a leading T-cell receptor (TCR) cell therapy company advancing a clinical-stage...
Alaunos Therapeutics to Present Early Data from TCR-T Library Phase 1/2 Trial at 2023 American Society of Clinical Oncology Annual Meeting
25 mai 2023 17h00 HE
|
Alaunos Therapeutics, Inc.
TCR-T cell therapy shows first-in-human response for non-viral TCR-T therapy; effectively targets high frequency TP53 and KRAS driver mutations across multiple solid tumor indicationsTreatment was...
Alaunos Therapeutics Reports First Quarter 2023 Financial Results
10 mai 2023 07h00 HE
|
Alaunos Therapeutics, Inc.
Actively enrolling patients and manufacturing cryopreserved products for TCR-T Library Phase 1/2 trial; expect to report interim data in the third quarter of 2023Fully prepaid loan with Silicon Valley...
Alaunos Therapeutics to Report First Quarter 2023 Financial Results on May 10, 2023
03 mai 2023 08h30 HE
|
Alaunos Therapeutics, Inc.
HOUSTON, May 03, 2023 (GLOBE NEWSWIRE) -- Alaunos Therapeutics, Inc. (“Alaunos” or the “Company”) (Nasdaq: TCRT), a leading T-cell receptor (TCR) cell therapy company advancing a clinical-stage...
Alaunos Therapeutics Announces Poster Presentation at the American Society of Clinical Oncology (ASCO) 2023 Annual Meeting
26 avr. 2023 12h30 HE
|
Alaunos Therapeutics, Inc.
HOUSTON, April 26, 2023 (GLOBE NEWSWIRE) -- Alaunos Therapeutics, Inc. (“Alaunos” or the “Company”) (Nasdaq: TCRT), a leading T-cell receptor (TCR) cell therapy company advancing a clinical-stage...
Alaunos Therapeutics Appoints Dr. Robert J. Hofmeister to Board of Directors
30 mars 2023 07h00 HE
|
Alaunos Therapeutics, Inc.
HOUSTON, March 30, 2023 (GLOBE NEWSWIRE) -- Alaunos Therapeutics, Inc. (“Alaunos” or the “Company”) (Nasdaq: TCRT), a leading T-cell receptor (TCR) cell therapy company advancing a clinical-stage...
Alaunos Therapeutics to Participate in Upcoming Investor Conferences in April
29 mars 2023 17h30 HE
|
Alaunos Therapeutics, Inc.
HOUSTON, March 29, 2023 (GLOBE NEWSWIRE) -- Alaunos Therapeutics, Inc. (“Alaunos” or the “Company”) (Nasdaq: TCRT), a leading T-cell receptor (TCR) cell therapy company advancing a clinical-stage...
Alaunos Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results
07 mars 2023 07h00 HE
|
Alaunos Therapeutics, Inc.
Generated cutting-edge translational data demonstrating safety, persistence and functionality of infused TCR-T cells in the tumor microenvironment; provides support for next generation TCR-T...